company background image
INSM

Insmed NasdaqGS:INSM Stock Report

Last Price

US$18.41

Market Cap

US$2.5b

7D

-5.6%

1Y

-36.4%

Updated

27 Nov, 2022

Data

Company Financials +
INSM fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

INSM Stock Overview

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.

Insmed Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Insmed
Historical stock prices
Current Share PriceUS$18.41
52 Week HighUS$30.49
52 Week LowUS$16.41
Beta1.58
1 Month Change5.14%
3 Month Change-23.83%
1 Year Change-36.36%
3 Year Change-20.13%
5 Year Change-40.58%
Change since IPO-88.84%

Recent News & Updates

Insmed inks financing agreements to raise $500M

Oct 19

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Oct 17
Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Recent updates

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Oct 17
Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

Sep 20
An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

Is Insmed (NASDAQ:INSM) A Risky Investment?

Jun 24
Is Insmed (NASDAQ:INSM) A Risky Investment?

Is Insmed (NASDAQ:INSM) Using Debt Sensibly?

Dec 11
Is Insmed (NASDAQ:INSM) Using Debt Sensibly?

Is Insmed (NASDAQ:INSM) Using Too Much Debt?

Sep 10
Is Insmed (NASDAQ:INSM) Using Too Much Debt?

Estimating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Jun 10
Estimating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

We Think The Compensation For Insmed Incorporated's (NASDAQ:INSM) CEO Looks About Right

May 06
We Think The Compensation For Insmed Incorporated's (NASDAQ:INSM) CEO Looks About Right

Is Insmed (NASDAQ:INSM) Weighed On By Its Debt Load?

Apr 06
Is Insmed (NASDAQ:INSM) Weighed On By Its Debt Load?

Have Insiders Been Selling Insmed Incorporated (NASDAQ:INSM) Shares?

Mar 02
Have Insiders Been Selling Insmed Incorporated (NASDAQ:INSM) Shares?

Did Business Growth Power Insmed's (NASDAQ:INSM) Share Price Gain of 224%?

Jan 26
Did Business Growth Power Insmed's (NASDAQ:INSM) Share Price Gain of 224%?

Is Insmed (NASDAQ:INSM) Weighed On By Its Debt Load?

Dec 22
Is Insmed (NASDAQ:INSM) Weighed On By Its Debt Load?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Insmed Incorporated (NASDAQ:INSM)

Nov 26
Don't Ignore The Fact That This Insider Just Sold Some Shares In Insmed Incorporated (NASDAQ:INSM)

Shareholder Returns

INSMUS BiotechsUS Market
7D-5.6%0.4%1.3%
1Y-36.4%-14.4%-18.5%

Return vs Industry: INSM underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: INSM underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is INSM's price volatile compared to industry and market?
INSM volatility
INSM Average Weekly Movement7.6%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: INSM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: INSM's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988613Will Lewishttps://www.insmed.com

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.

Insmed Incorporated Fundamentals Summary

How do Insmed's earnings and revenue compare to its market cap?
INSM fundamental statistics
Market CapUS$2.49b
Earnings (TTM)-US$434.39m
Revenue (TTM)US$242.18m

10.3x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INSM income statement (TTM)
RevenueUS$242.18m
Cost of RevenueUS$55.35m
Gross ProfitUS$186.84m
Other ExpensesUS$621.23m
Earnings-US$434.39m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.21
Gross Margin77.15%
Net Profit Margin-179.36%
Debt/Equity Ratio-2,619.6%

How did INSM perform over the long term?

See historical performance and comparison